Products
Rasburicase is commercially available as an injectable (Fasturtec). It has been approved in many countries since 2002.
Structure and properties
Rasburicase is a recombinant urate oxidase enzyme produced by a genetically modified strain of yeast.
Effects
The enzyme rasburicase (ATC V03AF07) catalyzes the enzymatic oxidation of uric acid into allantoin, a water-soluble substance that, unlike uric acid, is readily excreted by the kidneys. It thus lowers the concentration of hanic acid in the blood and counteracts hyperuricemia and renal dysfunction.
Indications
To prevent and treat acute excess uric acid in the blood (hyperuricemia) and thereby prevent acute renal impairment. Rasburicase is used in patients with leukemia or non-Hodgkin lymphoma at the start of chemotherapy.
Dosage
According to the SmPC. The drug is administered once daily as an intravenous infusion.
Contraindications
- Hypersensitivity
- G6PD deficiency and other metabolic disorders that can cause hemolytic anemia.
For complete precautions, see the drug label.
Interactions
Drug interactions with methemoglobinemia inducers may be possible.
Adverse effects
Possible adverse effects include hypersensitivity reactions, red blood cell dissolution, anemia, methemoglobinemia, headache, diarrhea, vomiting, nausea, and fever.
